Cargando…
Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
Introduction: TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We have reported a retrospective analysis of newly diagnosed Chinese GBM patients who received TTFields/TMZ treatment and TMZ treatment from A...
Autores principales: | Chen, Chunjui, Xu, Hao, Song, Kun, Zhang, Yi, Zhang, Junyan, Wang, Yang, Sheng, Xiaofang, Chen, Lingchao, Qin, Zhiyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570572/ https://www.ncbi.nlm.nih.gov/pubmed/36233722 http://dx.doi.org/10.3390/jcm11195855 |
Ejemplares similares
-
Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022) -
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
por: Guzauskas, Gregory F, et al.
Publicado: (2018) -
Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022) -
ES-2 Phase 3 TRIDENT Trial: Radiation and Temozolomide with or without Tumor Treating Fields in newly diagnosed glioblastoma
por: Nakada, Mitsutoshi
Publicado: (2020) -
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)